Dare Bioscience, Inc.
DARENasdaq
$1.96
↑ +1.0%Jul 17 close · end-of-day
Price
1Y↓ -25.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$28.5M
Enterprise Value
$9.9M
P/E
—
P/S
24.6
P/B
38.8
EV/EBITDA
—
PEG
—
FCF Yield
-35.7%
Dividend Yield
—
Revenue (TTM)
$1.2M
Net Income (TTM)
-$12.0M
Free Cash Flow (TTM)
-$10.2M
Gross Margin
—
Operating Margin
-1034.4%
Net Margin
-1038.8%
ROE
-1636.8%
ROIC
—
Debt / Equity
—
Net Cash
$18.5M
Return 1Y
-21.6%
Company profile
Daré Bioscience, Inc. develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive.
- CEO
- Sabrina M. Johnson
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- California
- Website
- darebioscience.com
Earnings
DARE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$152,455.00↑ +499.6%
Diluted EPS-$0.21↓ -58.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $10.0M | $2.8M | $9,784.00 | $1.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$27.4M | -$39.1M | -$31.4M | -$30.9M | -$23.5M | -$13.6M |
| Net income | -$27.4M | -$38.7M | -$30.9M | -$30.2M | -$4.0M | -$13.4M |
| Diluted EPS | -$0.91 | -$0.63 | -$0.37 | -$4.15 | -$0.48 | -$1.20 |
| Operating cash flow | -$25.2M | -$28.8M | -$18.1M | -$38.9M | $5.5M | -$9.9M |
| Free cash flow | -$25.3M | -$28.8M | -$18.2M | -$39.5M | $4.9M | -$10.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | -313.9% | -1101.9% | -239692.2% | -1315.5% |
| Net margin | — | — | -309.5% | -1074.1% | -41394.1% | -1300.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22,438.00 | $41,691.00 | -$63,647.00 | $25,427.00 | -$21,172.00 | $2,262.00 | $1.0M | $152,455.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$7.4M | -$4.7M | -$5.4M | -$4.6M | -$3.8M | -$3.7M | -$1.5M | -$3.0M |
| Net income | $12.9M | -$4.7M | -$5.5M | -$4.4M | -$4.0M | -$3.6M | -$1.4M | -$3.0M |
| Diluted EPS | $1.52 | -$0.55 | -$0.64 | -$0.50 | -$0.45 | -$0.28 | $0.03 | -$0.21 |
| Operating cash flow | $12.9M | -$5.9M | $5.3M | -$5.5M | -$5.4M | -$442,135.00 | $1.4M | -$5.5M |
| Free cash flow | $12.6M | -$6.2M | $4.7M | -$5.6M | -$5.6M | -$616,837.00 | $1.2M | -$5.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -32799.1% | -11228.7% | 8465.8% | -18016.7% | 18079.5% | -162340.8% | -143.7% | -1967.1% |
| Net margin | 57539.2% | -11279.4% | 8645.8% | -17219.1% | 18970.7% | -157505.1% | -140.9% | -1967.7% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Grossman Jessica D. | Award | 26,066 | $0.00 | $0.00 | filing |
| 2026-06-30 | Kelley Susan L. | Award | 23,696 | $0.00 | $0.00 | filing |
| 2026-06-30 | Matz Gregory W | Award | 30,805 | $0.00 | $0.00 | filing |
| 2026-06-30 | RASTETTER WILLIAM H | Award | 38,862 | $0.00 | $0.00 | filing |
| 2026-06-30 | Steele Robin Joan | Award | 26,540 | $0.00 | $0.00 | filing |
Latest 5 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.